Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.

Clinical Trial Description

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. CLL is a cancer of the B-lymphocytes, which make antibodies that help protect the body against harmful foreign substances, such as bacteria and viruses. Similar to CLL, small lymphocytic lymphoma (SLL) is a less-common cancer of the B-lymphocytes. In SLL, the abnormal lymphocytes mainly affect the lymph nodes; in CLL, the abnormal lymphocytes mainly affect the blood and bone marrow.

Current drug therapies for CLL/SLL are known to increase the severity of pre-existing low blood cell counts, which in turn increase the risk of infections in patients. Research to improve the safety and effectiveness of CLL/SLL therapy is currently ongoing. One such therapy being investigated is Rituximab.

Rituximab is a type of drug known as a therapeutic antibody. Therapeutic antibodies are laboratory-created substances that attach onto a protein on the surface of a cell. After binding to the cell, the therapeutic antibody can block the growth of the tumor and/or trigger the body's immune system to attack the target, and can also sensitize a cancer cell to chemotherapy. Rituximab is approved by the Food and Drug Administration (FDA) for the treatment of CLL/SLL.

Beta-Glucan (Imucell WGP) is an over-the-counter dietary supplement that enhances the body's immune system. ImucellTM WGP is extracted from food-grade baker's yeast, which is permitted for use in food by the FDA. Animal studies have shown that Imucell WGP helps trigger the white blood cells to destroy cancer cells. Other animal studies combining Rituximab with Imucell WGP have shown greater tumor regression and tumor-free survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00290407
Study type	Interventional
Source	University of Louisville
Contact
Status	Terminated
Phase	Phase 2
Start date	March 2006
Completion date	January 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03204188` - Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2
Completed	`NCT02758665` - Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL	Phase 2
Terminated	`NCT00393380` - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor	Phase 2
Terminated	`NCT00176930` - Stem Cell Transplant for Hematological Malignancy	N/A
Completed	`NCT00562224` - Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients	Phase 1
Completed	`NCT00186303` - Transplantation for Patients With Chronic Lymphocytic Leukemia	N/A
Completed	`NCT00270049` - Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia	Phase 2
Terminated	`NCT02440685` - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT00083473` - A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia	Phase 2
Completed	`NCT04030195` - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL	Phase 1/Phase 2
Completed	`NCT00464633` - Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)	Phase 2
Completed	`NCT00055146` - Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)	Phase 2
Not yet recruiting	`NCT05154474` - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Completed	`NCT00289549` - Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)	Phase 2
Terminated	`NCT01045382` - MSC and HSC Coinfusion in Mismatched Minitransplants	Phase 2
Terminated	`NCT01050946` - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit	Phase 2
Completed	`NCT00283101` - A Safety Study in Patients With Chronic Lymphocytic Leukemia	Phase 1/Phase 2
Completed	`NCT00546793` - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL	Phase 1/Phase 2
Terminated	`NCT00167180` - Post Transplant Donor Lymphocyte Infusion	Phase 2
Completed	`NCT00535912` - Phase III Study Treatment of CLL B and C	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms